Skip to main content
[Preprint]. 2023 Aug 21:2023.08.20.23294331. [Version 1] doi: 10.1101/2023.08.20.23294331

Figure 4: PGS associations with pharmacogenomic outcomes.

Figure 4:

(a) Odds-ratio of having an ICD-code for toxicity from an antineoplastic or immunosuppressive medication with (n=985) or without (n=2273) a clinical concern for a low WBC count among 71,078 BioVU participants. Odds-ratios are from a logistic regression model, adjusted for age, sex and principal components. (b) Kaplan-Meier plot for a WBC count<3,000 cells/ul (leukopenia) after initiating treatment with taxanes among 1,724 BioVU participants with cancer. The PGSWBC strata are: Low (<1 s.d. below the mean), Middle (≥ −1 s.d. and ≤ 1 s.d.), High (>1 s.d).